↑ 疾患リストへ ← 戻る

 89. リンパ脈管筋腫症 [臨床試験数:30,薬物数:28(DrugBank:17),標的遺伝子数:25,標的パスウェイ数:17] 

Searched query = "Lymphangioleiomyomatosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03253913March 31, 201811 June 2018Resveratrol and Sirolimus in Lymphangioleiomyomatosis TrialResveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)LymphangioleiomyomatosisDrug: Sirolimus;Drug: ResveratrolUniversity of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Recruiting18 YearsN/AFemale25Phase 2United States
2NCT03131999January 23, 201830 September 2019LAM Pilot Study With Imatinib MesylateLAM Pilot Study With Imatinib MesylateLymphangioleiomyomatosisDrug: Imatinib Mesylate 400Mg Capsule;Drug: Placebo - CapsuleMedical University of South CarolinaColumbia UniversityNot recruiting18 YearsN/AAll18Phase 1/Phase 2United States
3NCT03150914January 1, 201826 August 2019Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialMulticenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialLAM;LymphangioleiomyomatosisDrug: SirolimusUniversity of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS);The LAM FoundationRecruiting18 YearsN/AFemale60Phase 3United States
4NCT03062943October 201626 August 2019A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)LymphangioleiomyomatosisDrug: NintedanibIRCCS MultimedicaRecruiting18 YearsN/AFemale30Phase 2Italy
5NCT02737202April 20165 February 2018Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisSafety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisPulmonary LymphangioleiomyomatosisDrug: saracatinibBaylor College of MedicineUniversity of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH)Recruiting18 Years65 YearsFemale28Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-004919-20-IT09/03/201616 August 2016A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) - A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)Female subjects affected by Llymphangioleiomyomatosis (LAM)
MedDRA version: 19.0 Level: PT Classification code 10049459 Term: Lymphangioleiomyomatosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Ofev
Pharmaceutical Form: Capsule, soft
MULTIMEDICA S.P.A.AuthorisedFemale: yes
Male: no
30Phase 3Italy
7NCT02484664January 201628 January 2019COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSCCOLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSCLymphangioleiomyomatosis (LAM)Drug: CelecoxibBrigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 Years70 YearsFemale12Phase 2United States
8NCT02432560March 201514 October 2019Safety and Durability of Sirolimus for Treatment of LAMMulticenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)LymphangioleiomyomatosisDrug: Sirolimus;Drug: EverolimusUniversity of CincinnatiRare Diseases Clinical Research Network;National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);The LAM FoundationNot recruiting18 YearsN/AFemale600Phase 2United States
9JPRN-UMIN0000166772015/01/012 April 2019Efficacy and safety of low dose sirolimus in lymphangioleiomyomatosislymphangioleiomyomatosissirolimus 1mg/day / sirolimus 2mg/dayNational Hospital Organization Kinki-chuo Chest Medical CenterRecruitingNot applicableNot applicableMale and Female20Not selectedJapan
10NCT02116712August 201412 December 2016The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)Pulmonary LymphangioleiomyomatosisDrug: SaracatinibTony EissaUniversity of Texas;University of CincinnatiNot recruiting18 Years65 YearsBoth9Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02061397March 201425 February 2019Safety of Simvastatin in LAM and TSCThe Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)Lymphangioleiomyomatosis;Tuberous Sclerosis ComplexDrug: SimvastatinUniversity of PennsylvaniaThe LAM FoundationNot recruiting18 YearsN/AFemale10Phase 1/Phase 2United States
12NCT01799538June 10, 201311 November 2019Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis13-H-0051 Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With LymphangioleiomyomatosisLymphangioleiomyomatosisDrug: albuterol inhaler;Drug: albuterol nebulizer;Procedure: PFTNational Heart, Lung, and Blood Institute (NHLBI)Recruiting18 Years80 YearsFemale100Phase 1United States
13JPRN-JMA-IIA0009605/09/20122 April 2019multicenter lymphangioleiomyomatosis sirolimus trial for safetymulticenter lymphangioleiomyomatosis sirolimus trial for safetylymphangioleiomyomatosisIntervention type:DRUG. Intervention1:Srolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years and modified dosage between 1mg and 3mg QD depend on the plasma concentration monitoring..Koh Nakata, MD, PhDYoshikazu Inoue Kuniaki Seyama Ryushi Tazawa Toshinori TakadaNot Recruiting>=18 YEARSNo LimitFemale65Phase 2Japan
14NCT01687179September 201222 August 2016Safety Study of Sirolimus and Hydroxychloroquine in Women With LymphangioleiomyomatosisTargeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and SirolimusLymphangioleiomyomatosisDrug: sirolimus and hydroxychloroquineBrigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 Years85 YearsFemale14Phase 1United States
15JPRN-UMIN0000073872012/03/312 April 2019Clinical trials for long-term administration of sirolimus for lymphangioleiomyomatosislymphangioleiomyomatosissirolimusKobe University Graduate School of MedicineRecruitingNot applicableNot applicableFemale1Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT01552434March 16, 201230 September 2019Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseA Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsAdvanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland NeoplasmBiological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic AcidM.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingN/AN/AAll216Phase 1United States
17JPRN-JMA-IIA0003701/10/20112 April 2019MLLTS trialMulticenter Lymphangioleiomyomatosis Long Term Sirolimus TriallymphangioleiomyomatosisIntervention type:DRUG. Intervention1:sirolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:LAM patients will be medicated with 2mg of sirolimus every day for 2 years..Koh Nakata, MD, Ph.DRyushi TazawaNot Recruiting>=18 YEARSNo LimitFemale50Phase 2Japan
18NCT01353209May 20117 September 2015Trial of Aromatase Inhibition in LymphangioleiomyomatosisA TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSISLymphangioleiomyomatosisDrug: Letrozole;Drug: PlaceboUniversity of CincinnatiDepartment of DefenseNot recruiting18 YearsN/AFemale17Phase 2United States
19EUCTR2010-019825-32-IT28/07/201018 March 2013An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. - NDAn exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. - NDLymphangioleiomyomatosis
MedDRA version: 12.1 Level: LLT Classification code 10049459 Term: Lymphangioleiomyomatosis
Pharmaceutical Form: Tablet
INN or Proposed INN: Everolimus
Current Sponsor code: RAD001
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical Form: Tablet
INN or Proposed INN: Everolimus
Current Sponsor code: RAD001
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical Form: Tablet
INN or Proposed INN: Everolimus
Current Sponsor code: RAD001
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
NOVARTIS FARMANot RecruitingFemale: yes
Male: no
24France;Italy
20NCT01059318December 200919 February 2015A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With LymphangioleiomyomatosisAn Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With LymphangioleiomyomatosisLymphangioleiomyomatosisDrug: EverolimusNovartis PharmaceuticalsNot recruiting18 YearsN/AFemale22Phase 2United States;France;Germany;Italy
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00989742July 200914 December 2015Doxycycline In Lymphangioleiomyomatosis (LAM)A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.Lymphangioleiomyomatosis;Tuberous SclerosisDrug: Doxycycline;Drug: PlaceboUniversity of NottinghamNot recruiting18 YearsN/AFemale24Phase 4United Kingdom
22NCT00790400April 200916 December 2017Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC);Lymphangioleiomyomatosis (LAM)Drug: Everolimus (RAD001);Drug: Everolimus PlaceboNovartis PharmaceuticalsNot recruiting18 YearsN/AAll118Phase 3United States;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom
23EUCTR2007-003745-32-GB12/12/200830 June 2014A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAMA randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAMLymphangioleiomyomatosis
MedDRA version: 9.1 Level: LLT Classification code 10049459 Term: Lymphangioleiomyomatosis
MedDRA version: 9.1 Level: PT Classification code 10049459 Term: Lymphangioleiomyomatosis
Trade Name: Doxycycline 100 mg Capsules
Pharmaceutical Form: Capsule*
INN or Proposed INN: doxycycline
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
University of NottinghamNot RecruitingFemale: yes
Male: no
United Kingdom
24NCT00792766December 200819 February 2015Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;AngiolipomaDrug: everolimus (RAD001)Children's Hospital Medical Center, CincinnatiNovartisNot recruiting18 Years65 YearsBoth20Phase 1/Phase 2United States
25JPRN-JMA-IIA0001108/05/20082 April 2019Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial)Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial)Lymphangioleiomyomatosis (LAM)Intervention type:DRUG. Intervention1:Sirolimus, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:12 months on, 12 months off. Control intervention1:Placebo, Dose form:TABLET, Route of administration:ORAL, Intended dose regimen:12 months on, 12 months off.Frank McCormack, M.D., University of Cincinnati Medical Center Director, Division of Pulmonary and Critical Care Medicinea. Alan F. Barker, M.D. - Oregon Health & Sciences University b. Kevin Brown, M.D., - National Jewish Medical & Research Center c. Edwin K. Silverman, M.D., Ph.D. - Harvard/Brigham & Women's Hospital d. James M. Stocks, M.D. - University of Texas Health Center e. James K. Stoller, M.D. - Cleveland Clinic Foundation f. Charlie Strange, M.D. - Medical University of South Carolina g. Bruce Trapnell, M.D.-Cincinnati Children's Medical Center h. Mark Brantly, M.D.-University of Florida, Gainesville i. Yosdhikazu Inoue, M.D., National Hospital Organization (NHO) Kinki-Chuo Chest Medical Center j. Koh Nakata, M.D., Ph.D., Bioscience Medical Research Center, Niigata University Medical and Dental Hospital k. Joel Moss, M.D., Ph.D-National Institutes of HealthNot Recruiting>=18 YEARSFemale120Phase 3Japan, United States, Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT00414648December 200619 February 2015Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)Lymphangioleiomyomatosis Efficacy and Safety TrialLymphangioleiomyomatosisDrug: Sirolimus;Drug: Placebo sirolimusOffice of Rare Diseases (ORD)FDA Office of Orphan Products DevelopmentNot recruiting18 YearsN/AFemale120Phase 3United States;Canada;Japan
27NCT00490789October 200519 February 2015Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMA Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;LymphangioleiomyomatosisDrug: sirolimusCardiff UniversityUniversity of Nottingham;St Georges Hospital Medical School;Royal Sussex County Hospital;The Tuberous Sclerosis Association;Wyeth is now a wholly owned subsidiary of PfizerNot recruiting18 Years65 YearsBoth14Phase 2United Kingdom
28NCT00457964August 200519 February 2015RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMRAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;LymphangioleiomyomatosisDrug: RAD001Children's Hospital Medical Center, CincinnatiNovartis PharmaceuticalsNot recruiting18 Years65 YearsBoth36Phase 1/Phase 2United States
29NCT00457808December 200219 February 2015Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMRapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic LymphangioleiomyomatosisTuberous Sclerosis;LymphangioleiomyomatosisDrug: Rapamycin, sirolimusChildren's Hospital Medical Center, CincinnatiThe LAM Foundation;Tuberous Sclerosis AllianceNot recruiting18 Years65 YearsBoth25Phase 2United States
30NCT00005906June 200019 October 2017Treatment With Octreotide in Patients With LymphangioleiomyomatosisTreatment With Octreotide in Patients With LymphangioleiomyomatosisLymphangioleiomyomatosis;Lymphangiomyomas;Pleural Effusions;AscitesDrug: OctreotideNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 Years65 YearsFemale4Phase 2United States

先頭へ